Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Replies to post #168582 on Biotech Values
DewDiligence
02/04/14 4:24 PM
#173734 RE: genisi #168582
Myriad Genetics, Inc. (MYGN) announced today that it has entered into a definitive agreement to acquire Crescendo Bioscience, Inc., a global leader in autoimmune diagnostics, for $270 million in cash… … Crescendo was founded in July 2002 and is a leading molecular diagnostic laboratory in the area of inflammatory and autoimmune diseases. Their core product, Vectra(R) DA, is a quantitative, protein-based test to routinely assess rheumatoid arthritis disease activity and provide rheumatologists with expanded clinical insights to more effectively treat their patients.